Marshall Wace LLP Boosts Stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Marshall Wace LLP grew its position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 17,912.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,778,497 shares of the company’s stock after purchasing an additional 2,763,072 shares during the period. Marshall Wace LLP’s holdings in Maravai LifeSciences were worth $15,143,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. SG Americas Securities LLC grew its position in shares of Maravai LifeSciences by 7.3% during the fourth quarter. SG Americas Securities LLC now owns 33,046 shares of the company’s stock worth $180,000 after buying an additional 2,239 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Maravai LifeSciences by 10.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 30,076 shares of the company’s stock worth $164,000 after acquiring an additional 2,851 shares in the last quarter. Performa Ltd US LLC increased its position in shares of Maravai LifeSciences by 614.3% in the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock valued at $27,000 after purchasing an additional 4,300 shares during the last quarter. FNY Investment Advisers LLC raised its holdings in shares of Maravai LifeSciences by 600.0% in the 4th quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock valued at $38,000 after purchasing an additional 6,000 shares in the last quarter. Finally, Bleakley Financial Group LLC lifted its position in shares of Maravai LifeSciences by 30.1% during the 4th quarter. Bleakley Financial Group LLC now owns 41,691 shares of the company’s stock worth $227,000 after purchasing an additional 9,657 shares during the last quarter. 50.25% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Maravai LifeSciences

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $5.03, for a total value of $125,750.00. Following the transaction, the general counsel now owns 167,618 shares of the company’s stock, valued at approximately $843,118.54. The trade was a 12.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.63% of the stock is owned by company insiders.

Maravai LifeSciences Trading Up 2.9 %

NASDAQ MRVI opened at $1.77 on Monday. The firm’s fifty day moving average is $2.67 and its two-hundred day moving average is $4.81. Maravai LifeSciences Holdings, Inc. has a one year low of $1.56 and a one year high of $11.56. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74. The firm has a market cap of $450.17 million, a PE ratio of -1.08 and a beta of 0.18.

Wall Street Analyst Weigh In

A number of research firms have recently commented on MRVI. Robert W. Baird downgraded Maravai LifeSciences from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $9.00 to $3.00 in a report on Wednesday, February 26th. Baird R W cut shares of Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Stifel Nicolaus set a $5.00 price objective on shares of Maravai LifeSciences in a research report on Friday, March 21st. UBS Group dropped their target price on shares of Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating on the stock in a research report on Friday, March 21st. Finally, Morgan Stanley reduced their price target on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 25th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $6.34.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.